Results 181 to 190 of about 17,718 (201)

Ranibizumab for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine, 2006
Philip J Rosenfeld, Jeffrey S Heier, David S Boyer   +2 more
exaly  

Ranibizumab for Macular Edema following Central Retinal Vein Occlusion

Ophthalmology, 2010
Peter A Campochiaro, Rishi P Singh
exaly  

Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine, 2011
Maureen G Maguire, Gui-shuang Ying, Juan E Grunwald   +2 more
exaly  

Ranibizumab

Reactions Weekly, 2014
  +4 more sources

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

New England Journal of Medicine, 2015
Lee M Jampol, Michael J Elman, Jennifer K Sun   +2 more
exaly  

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine, 2006
Peter K Kaiser, Jeffrey S Heier
exaly  

A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study

American Journal of Ophthalmology, 2009
Philip J Rosenfeld, Harry W Flynn
exaly  

Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results

Ophthalmology, 2015
Michael J Elman, Lee M Jampol
exaly  

An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular Degeneration

American Journal of Ophthalmology, 2007
Philip J Rosenfeld, Harry W Flynn
exaly  

Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III Study

Ophthalmology, 2011
Peter A Campochiaro
exaly